Metastatic Male Breast Cancer Responding to Abemaciclib and Letrozole

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: ER-positive, PR-negative, HER2-negative

Metastatic Site: soft tissue, distant lymph nodes, bone

The tumor and metastatic soft-tissue and lymph-node disease shrank markedly, with no progression on July 2024 imaging and good clinical condition in September 2024.

PubMed CentralRead more →

Severe Corneal Injury After Trastuzumab for Metastatic HER2-Positive Breast Cancer

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-positive

Metastatic Site: lungs, spine, left adrenal gland, calvarium, orbit,…

She was living with widespread metastatic breast cancer when trastuzumab was stopped because of severe eye toxicity.

PubMed CentralRead more →

Stage IV HR-Positive Invasive Ductal Carcinoma: Dee's Patient Story

Patient Info: Dee, Female, Under 40 | Stage IV

Biomarkers: ER-positive

Metastatic Site: Bones

As of October 2024, Dee was living with Stage IV metastatic ER-positive breast cancer after bone metastases were found in 2023 and had adapted to treatment with ribociclib.

The Patient StoryRead more →

Stage IV HER2-Positive Invasive Ductal Carcinoma: Dee's Patient Story

Patient Info: Dee Doherty, Female, Under 40 | Stage IV

Biomarkers: Hormone-sensitive disease implied by letrozole and ovarian suppression; ER/PR/HER2 status not explicitly stated

Metastatic Site: bone

As of September 2024, Dee was living with Stage IV metastatic breast cancer. Her tumors had not shrunk, but disease was stable on ribociclib/Kisqali, letrozole, and ovarian suppression.

The Patient StoryRead more →

Stage III HER2-Positive Occult Breast Cancer With a Complete Response to Treatment

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: HER2-positive

Surgery after neoadjuvant treatment found no residual tumor in the breast or 20 examined lymph nodes, indicating a complete pathologic response; HER2-targeted therapy continued afterward.

PubMed CentralRead more →

Stage II HER2-Positive Breast Cancer With Fever and a Reversible Brain MRI Lesion After Radiotherapy

Patient Info: Anonymized, Female, Under 40 | Stage II

Biomarkers: ER-positive, PR-positive, HER2-positive

After radiotherapy, fever, neutropenia, headache, and a reversible splenial brain lesion resolved with supportive and antibiotic treatment during her postoperative breast-cancer treatment course.

PubMed CentralRead more →

Stage IV Breast Cancer: Lourdes's Patient Story

Patient Info: Lourdes Monje, Under 40 | Stage IV

Metastatic Site: lung

Lourdes is receiving investigational treatment through a clinical trial, with manageable side effects, while continuing to work and spend time with family and friends.

Stage 4 breast cancer: complete remission with letrozole and palbociclib

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Breast cancer was ER/PR positive, HER2 0

Metastatic Site: pleura/pleural effusion

Breast cancer remained in remission on letrozole after palbociclib was stopped; Ph-positive B-ALL achieved complete response with no molecular residual disease after blinatumomab plus ponatinib, with ongoing monthly outpatient monitoring.

PubMed CentralRead more →

Invasive Lobular Carcinoma: Kristie's Survivor Story

Patient Info: Kristie, Female

As of August 2024, Kristie was focused on survivorship and advocacy after extensive ILC treatment that included 20 weeks of chemotherapy, 25 radiation treatments, 2 years on Verzenio, estrogen blockers, and 5 surgeries.

Lobular Breast Cancer AllianceRead more →

Right-Sided Ductal Carcinoma in Situ Before a Second Breast Cancer

Patient Info: Anonymized, female, 60s

Biomarkers: ER-positive; PR-positive; HER2 1+

A woman treated for right-sided ductal carcinoma in situ in 2018 later developed a separate invasive cancer in the opposite breast.

PubMed CentralRead more →

HER2-Positive Breast Cancer That Spread to the Cervix

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: HER2-positive; ER and PR less than 1% in the left breast tumor

Metastatic Site: cervix, esophagus, mediastinal lymph nodes

Cervical metastasis showed a local complete response after brachytherapy, but systemic disease later progressed to the esophagus. She died after 4 months of nutritional support and palliative treatment.

PubMed CentralRead more →

Stage 4 invasive ductal carcinoma: metastatic disease with bone involvement managed successfully

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER <1%; PR 0%; HER2 score 3+; Ki-67 60%

Metastatic Site: bone (12th thoracic vertebra/T12)

Stage IV HER2-positive breast cancer had improved T12 bone metastasis, major breast-tumor regression on trastuzumab deruxtecan, and pathologic complete response in the breast after mastectomy; durable systemic disease status was not reported.

PubMed CentralRead more →

Breast cancer history with painful implant capsule: no recurrence or BIA-ALCL found

Patient Info: Anonymized, Female, 40s

Biomarkers: Implant/capsule pathology showed necrotic tissue only; no tumor cells, CD30 signal, bacteria

The painful implant/capsule episode did not show breast cancer recurrence or BIA-ALCL on pathology; symptoms and cancer concern improved after implant removal, while oral flumatinib maintenance for acute B-lymphoblastic leukemia continued.

PubMed CentralRead more →

Metastatic HER2-Positive Breast Cancer Complicated by Recurrent Treatment-Related Heart Failure

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: HER2-positive

Heart function improved after the cancer regimen was changed, but she later died from septic shock caused by bile duct obstruction.

PubMed CentralRead more →

Triple-positive breast cancer: complete response to targeted therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Triple-positive breast cancer; SBDS variants present; no detected TP53 variant on MyeloSeq.

Metastatic Site: liver

Stage IV triple-positive breast cancer with liver metastasis achieved complete response after paclitaxel, trastuzumab, pertuzumab, and G-CSF support; complete response was maintained for 18 months after treatment initiation while on maintenance HER2-directed and endocrine therapy.

PubMed CentralRead more →

Stage IV Breast Cancer: Samantha's Patient Story

Patient Info: Samantha, Female, Under 40 | Stage IV

Biomarkers: Hormone-positive breast cancer; specific receptor details not reported

Metastatic Site: bone: rib, spine, pelvis

As of July 2024, Samantha was living with Stage IV hormone-positive breast cancer with bone metastases. Current treatment was working in most areas, but a breast tumor continued to grow and was surgically removed; ongoing treatment and 3-month scans were reported.

YouTube — The Patient StoryRead more →

HR-positive HER2-negative metastatic breast cancer: bone metastases managed with sequential endocrine therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER 90%+, PR 80%+, HER2-. CA 15-3 was tracked during treatment.

Metastatic Site: skull base; spine; sternum; ribs; left iliac bone;…

Metastatic HR-positive, HER2-negative breast cancer remained under active management; after earlier progression, palbociclib plus fulvestrant and zoledronic acid produced stable/remission findings on PET/CT at 3 months and again 1 year later, with continued 3-month follow-up recommended.

PubMed CentralRead more →

HER2-positive breast cancer: surgery after neoadjuvant therapy

Patient Info: Anonymized, Female, 60s | Stage I

Biomarkers: ER 1% weakly positive; PR-negative; HER2-positive

No evidence of disease on follow-up while taking anastrozole after pathologic complete response to neoadjuvant T-DM1, lumpectomy/SLNB, radiotherapy, and adjuvant trastuzumab for Stage I HER2-positive breast cancer.

PubMed CentralRead more →

HER2-positive Stage I breast cancer: residual microinvasion after neoadjuvant T-DM1

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: ER-negative; PR-negative; HER2-positive

No evidence of disease on follow-up after neoadjuvant T-DM1, lumpectomy/SLNB showing only residual microinvasion/DCIS, continued adjuvant T-DM1 to 17 total cycles, and 52.5 Gy radiotherapy.

PubMed CentralRead more →

Stage IV triple-negative breast cancer in remission: CBD and exercise for neuropathy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Triple-negative breast cancer. Blood and immune inflammation measures were tracked during neuropathy care.

Metastatic Site: liver

She was in remission for more than 5 years after Stage IV breast cancer with a solitary liver metastasis, while later managing chemotherapy-induced peripheral neuropathy with CBD and an exercise program that improved symptoms and function.

PubMed CentralRead more →

Stage IV Breast Cancer: Lisa's Patient Story

Patient Info: Lisa Ordmandy, Female, 60s | Stage IV

Metastatic Site: Spine/bone: C2 and L3 vertebrae

As of June 2024, Lisa was living with metastatic breast cancer as a chronic illness, had recovered mobility after November 2023 spine surgery, continued close MD Anderson monitoring, and was being evaluated for possible clinical trials.

MD AndersonRead more →

Stage III HR-Positive Invasive Lobular Carcinoma: Liz's Patient Story

Patient Info: Liz O'Riordan, Female, 40s | Stage III

Biomarkers: ER-positive; HER2-negative; PIK3CA mutation reported by patient

As of June 2024, Liz described Stage III ER-positive/HER2-negative mixed ductal and lobular breast cancer followed by 2 locoregional recurrences after mastectomy; no distant metastatic disease was described for her personal story.

YouTube — Dr Liz O'RiordanRead more →

BRCA2-mutant metastatic breast cancer: complete response with rucaparib maintenance

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: Germline BRCA2 mutation; somatic BRCA2 mutation; HER2 amplification not seen by FISH; grade III IDC

Metastatic Site: bone

She maintained a complete response for 2 years on rucaparib, letrozole, and zoledronic acid after upfront metastatic BRCA2-mutated breast cancer involving bone, axillary nodes, and right-breast nodules.

PubMed CentralRead more →

HER2-Positive Breast Cancer: Irasema's Survivor Story

Patient Info: Irasema Partida Chavez, Female

Biomarkers: HER2-positive

Irasema reported no evidence of breast cancer for 3 years after surgery and HER2-targeted treatment.